Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Is IVL safe for patients with diabetes?
New two-year data confirm that the IVL technology developed by Shockwave Medical can be used to treat diabetic patients who require PCI.
CPT code updates in 2026 will change how interventional cardiologists get paid
A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.
M-TEER still beneficial for high-risk patients with smaller mitral valve areas
Mitral valve surgery can be especially challenging when patients present with a small mitral valve area. When it comes to M-TEER, however, treatment still appears to be both safe and effective.
Match Day results put spotlight on interventional cardiology’s workforce woes
Interventional cardiology's second Match Day was a significant success. Due to a lack of candidates, however, dozens of fellowship positions remain unfilled.
TAVR still a safe treatment option for immunocompromised patients
While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

Is IVL safe for patients with diabetes?

New two-year data confirm that the IVL technology developed by Shockwave Medical can be used to treat diabetic patients who require PCI.

Arnold Seto, MD, MPA, FACC, FSCAI, cath lab director, Long Beach VA Medical Center, professor of medicine at Charles Drew University, Society for Cardiovascular Angiography and Interventions (SCAI) treasurer and chair of the SCAI Advocacy Committee, explains the new CPT reimbursement codes being introduced in January 2026 and their impact on practice.

CPT code updates in 2026 will change how interventional cardiologists get paid

A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.

M-TEER still beneficial for high-risk patients with smaller mitral valve areas

Mitral valve surgery can be especially challenging when patients present with a small mitral valve area. When it comes to M-TEER, however, treatment still appears to be both safe and effective.

medical students artificial intelligence AI

Match Day results put spotlight on interventional cardiology’s workforce woes

Interventional cardiology's second Match Day was a significant success. Due to a lack of candidates, however, dozens of fellowship positions remain unfilled.

TAVR still a safe treatment option for immunocompromised patients

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

Pope welcomes cardiologists to Vatican City

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.”

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.

heart doctors and surgeons working together. top cardiology hospitals in the United States.

Interventional cardiology groups unite to push the specialty forward

SCAI and CRT have announced a new partnership focused on education, advocacy and research.